Literature DB >> 9246141

Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis.

M E Dodd1, J Abbott, J Maddison, A J Moorcroft, A K Webb.   

Abstract

BACKGROUND: Inhalation of hypertonic nebulised colistin causes chest tightness and is a reason for discontinuing the treatment. This study examines the relationship of chest tightness and change in lung function in response to the inhalation of a range of tonicities of nebulised colistin and their influence on patients' preference.
METHODS: Twenty seven adult patients with cystic fibrosis and a mean forced expiratory volume in one second (FEV1) of 54% predicted (range 24-98) were studied. They inhaled a nebulised solution of hypertonic, isotonic, and hypotonic colistin over three consecutive days in random order in a double blind fashion. Measurements of chest tightness, using a visual analogue scale (VAS), and FEV1 were recorded before and 0, 15, 30, 60, and 90 minutes following inhalation. The solution preferred by each patient was determined at the end of the three days.
RESULTS: All tonicities caused a significant fall in FEV1 % predicted and an increase in chest tightness, with no differences between the solutions. However, the mean (SE) time to the maximum fall in FEV1 % predicted was significantly different between the solutions (hypertonic 7.8 (2.1) min, isotonic 19.2 (5.5) min, and hypotonic 34.2 (5.9) min) with a mean difference (95% CI) between hypotonic and hypertonic solutions of 28.04 (14.6 to 41.5) min, between isotonic and hypertonic solutions of 12.0 (-0.1 to 24.1) min, and between hypotonic and isotonic solutions of 15.6 (1.8 to 29.4) min. Positive correlations existed for the maximum fall in FEV1 % predicted between the hypertonic and isotonic solutions (r = 0.62, p < 0.001) and between the hypotonic and isotonic solutions (r = 0.64, p < 0.001). There was no correlation between the objective and subjective measurements for any solution. The patients' preference varied.
CONCLUSIONS: All tonicities of colistin caused equal symptoms of chest tightness and reduction in pulmonary function. It is recommended that the patient is challenged with nebulised colistin before prescription of the drug and that the challenge is preceded by an inhaled bronchodilator. Most of the patients preferred the isotonic or hypotonic solutions. The isotonic solution reflects a fall in FEV1 representative of all the solutions. The fall in FEV1 to the hypotonic solution occurred over a longer period and may be better tolerated by some patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9246141      PMCID: PMC1758594          DOI: 10.1136/thx.52.7.656

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  12 in total

1.  Further studies on the structural requirements for polypeptide-mediated histamine release from rat mast cells.

Authors:  B Jasani; G Kreil; B F Mackler; D R Stanworth
Journal:  Biochem J       Date:  1979-09-01       Impact factor: 3.857

2.  Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Authors:  M E Hodson; A R Penketh; J C Batten
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

3.  Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis.

Authors:  J M Littlewood; M G Miller; A T Ghoneim; C H Ramsden
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

4.  Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment.

Authors:  N H Valerius; C Koch; N Høiby
Journal:  Lancet       Date:  1991-09-21       Impact factor: 79.321

5.  Nebulized colistin causes chest tightness in adults with cystic fibrosis.

Authors:  J Maddison; M Dodd; A K Webb
Journal:  Respir Med       Date:  1994-02       Impact factor: 3.415

6.  Changes in the normal maximal expiratory flow-volume curve with growth and aging.

Authors:  R J Knudson; M D Lebowitz; C J Holberg; B Burrows
Journal:  Am Rev Respir Dis       Date:  1983-06

7.  Bronchial response to nebulized antibiotics in children with cystic fibrosis.

Authors:  H L Chua; G G Collis; P N Le Souëf
Journal:  Eur Respir J       Date:  1990-11       Impact factor: 16.671

8.  Bronchial hyperreactivity in response to inhalation of ultrasonically nebulised solutions of distilled water and saline.

Authors:  R E Schoeffel; S D Anderson; R E Altounyan
Journal:  Br Med J (Clin Res Ed)       Date:  1981-11-14

9.  Comparison of efficacy of salbutamol and sodium cromoglycate in the prevention of ticarcillin-induced bronchoconstriction.

Authors:  H L Chua; S L Walker; P N LeSouëf; P D Sly
Journal:  Pediatr Pulmonol       Date:  1993-11

10.  Treatment compliance in adults with cystic fibrosis.

Authors:  J Abbott; M Dodd; D Bilton; A K Webb
Journal:  Thorax       Date:  1994-02       Impact factor: 9.139

View more
  18 in total

1.  Bronchoconstriction following nebulised colistin in cystic fibrosis.

Authors:  S Cunningham; A Prasad; L Collyer; S Carr; I B Lynn; C Wallis
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

2.  Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis.

Authors:  N M Byrne; P M Keavey; J D Perry; F K Gould; D A Spencer
Journal:  Arch Dis Child       Date:  2003-08       Impact factor: 3.791

Review 3.  Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia.

Authors:  G Christopher Wood; Joseph M Swanson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  New and emerging therapies for pulmonary complications of cystic fibrosis.

Authors:  M R Tonelli; M L Aitken
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Colistin bladder instillation, an alternative way of treating multi-resistant Acinetobacter urinary tract infection: a case series and review of literature.

Authors:  R Giua; C Pedone; L Cortese; R Antonelli Incalzi
Journal:  Infection       Date:  2013-07-25       Impact factor: 3.553

Review 6.  Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects.

Authors:  Garyphallia Poulakou; Dimitrios K Matthaiou; David P Nicolau; Georgios Siakallis; George Dimopoulos
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

7.  Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis.

Authors:  Kate H Regan; Jayesh Bhatt
Journal:  Cochrane Database Syst Rev       Date:  2019-04-18

Review 8.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 9.  Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Authors:  Daniel Conole; Gillian M Keating
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

Review 10.  Nebulized antibiotics in cystic fibrosis.

Authors:  Isabelle Sermet-Gaudelus; Yann Le Cocguic; Agnés Ferroni; Marlène Clairicia; Joel Barthe; Jan-Pierre Delaunay; Valentine Brousse; Gérard Lenoir
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.